TheraRadar
← Back
Data updated: Jun 28, 2026

MELINTA

Pharma
Infectious DiseaseDermatologyGastroenterology Execution: Excellent

MELINTA is a pharmaceutical company focused on Infectious Disease, Dermatology, Gastroenterology. Key products include BAXDELA.

2017
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

FDA Novel Drug Designations

(2017)
1 Novel 1 Priority Review 1 Fast Track
See 1 novel approval →
2017 BAXDELA (DELAFLOXACIN MEGLUMINE) Priority Review · Fast Track

MELINTA at a Glance

  • Strong track record with 84% execution quality across 29 trials
  • Fast trial execution (11 months median completion)

Upcoming FDA Decisions

Full Calendar →
Jan 20, 2027 — Foundayo (orforglipron)

MELINTA's Key Drugs

MELINTA's core commercial portfolio centers on BAXDELA, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.

BAXDELA
Infectious Disease

Acute Bacterial Skin and Skin Structure Infections

Approved 2017

MELINTA's Recent FDA Approvals

New NDA/BLA approvals for MELINTA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MELINTA's Therapeutic Areas

MELINTA's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 75%
1 drugs Phase 3: 10 Phase 2: 7 Phase 1: 5
Dermatology 24%
1 drugs Phase 3: 2 Phase 2: 3 Phase 1: 1
Gastroenterology 1%
0 drugs Phase 1: 1

MELINTA's Top Competitors

MELINTA's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, Pfizer, and PF PRISM CV. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

APOTHECON specialty
Infectious Disease, Dermatology, Gastroenterology
Pfizer big-pharma
Infectious Disease, Dermatology
PF PRISM CV big-pharma
Infectious Disease, Dermatology, Gastroenterology
Baxter specialty
Infectious Disease, Dermatology
Johnson & Johnson big-pharma
Infectious Disease, Gastroenterology

MELINTA Pipeline Snapshot

MELINTA has 29 active clinical programs from ClinicalTrials.gov — 12 Phase 3, 10 Phase 2 and 7 Phase 1.

12
Phase 3
10
Phase 2
7
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • BAXDELA leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 9/11 completed
  • • Speed: 11 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges